Profile data is unavailable for this security.
About the company
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
- Revenue in USD (TTM)0.00
- Net income in USD-46.13m
- Incorporated2018
- Employees56.00
- LocationPulse Biosciences Inc3957 Point Eden WayHAYWARD 94545-3720United StatesUSA
- Phone+1 (510) 906-4600
- Fax+1 (302) 655-5049
- Websitehttps://www.pulsebiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Standard Biotools Inc | 155.90m | -170.60m | 763.13m | 534.00 | -- | 1.56 | -- | 4.89 | -0.7091 | -0.7091 | 0.5579 | 1.31 | 0.3054 | 2.48 | 6.01 | 291,951.30 | -24.41 | -28.17 | -29.37 | -33.60 | 48.57 | 51.58 | -79.91 | -74.85 | 3.41 | -- | 0.1014 | -- | 8.57 | -1.20 | 60.73 | -- | 50.06 | -- |
| Figs Inc | 548.65m | 10.84m | 804.75m | 354.00 | 79.82 | 1.98 | 48.59 | 1.47 | 0.059 | 0.059 | 3.08 | 2.38 | 1.11 | 1.33 | 65.26 | 1,549,845.00 | 2.20 | -- | 2.64 | -- | 67.67 | -- | 1.97 | -- | 3.28 | -- | 0.00 | -- | 7.87 | -- | 6.85 | -- | -- | -- |
| Embecta Corp | 1.12bn | 69.70m | 898.42m | 2.20k | 12.91 | -- | 8.30 | 0.803 | 1.21 | 1.21 | 19.36 | -13.24 | 0.8882 | 2.11 | 11.60 | 508,590.90 | 5.53 | -- | 7.91 | -- | 66.42 | -- | 6.23 | -- | 1.61 | 2.06 | 1.88 | -- | -0.7703 | -- | -68.52 | -- | -- | -- |
| Avanos Medical Inc | 681.50m | 21.70m | 914.54m | 3.77k | 42.53 | 0.7437 | 13.53 | 1.34 | 0.4679 | 0.3385 | 14.70 | 26.76 | 0.4031 | 1.90 | 5.16 | 180,721.30 | 1.28 | -0.6527 | 1.45 | -0.7338 | 55.51 | 54.45 | 3.18 | -1.60 | 1.46 | 9.84 | 0.1164 | -- | -1.58 | 0.6357 | -146.05 | -- | -18.37 | -- |
| Castle Biosciences Inc | 311.88m | 6.08m | 918.08m | 610.00 | 163.97 | 2.08 | 47.01 | 2.94 | 0.1999 | 0.1999 | 11.07 | 15.77 | 0.6562 | 9.15 | 7.15 | 511,275.40 | 1.28 | -9.43 | 1.40 | -10.17 | 81.90 | 80.58 | 1.95 | -28.46 | 7.64 | -- | 0.0228 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Cytek Biosciences Inc | 201.21m | -10.16m | 925.80m | 645.00 | -- | 2.37 | -- | 4.60 | -0.0782 | -0.0782 | 1.52 | 2.97 | 0.3982 | 1.60 | 3.72 | 297,647.90 | -2.01 | -- | -2.29 | -- | 54.92 | -- | -5.05 | -- | 5.47 | -- | 0.0083 | -- | 17.67 | -- | -571.58 | -- | -- | -- |
| Bioventus Inc | 555.06m | -39.48m | 960.87m | 1.03k | -- | 6.46 | -- | 1.73 | -0.6172 | -0.6172 | 8.68 | 1.83 | 0.7023 | 1.95 | 4.73 | 572,227.80 | -6.47 | -5.52 | -9.13 | -7.27 | 67.00 | 68.25 | -9.22 | -10.94 | 0.9866 | 1.13 | 0.6725 | -- | 0.0445 | 9.93 | 6.91 | -- | 23.51 | -- |
| Owens & Minor, Inc. | 10.66bn | -48.79m | 997.02m | 13.70k | -- | 1.14 | 4.50 | 0.0935 | -0.6346 | -0.6346 | 139.27 | 11.35 | 2.09 | 7.26 | 15.86 | 778,172.30 | -0.9561 | 1.32 | -1.49 | 2.07 | 20.72 | 16.48 | -0.4576 | 0.5614 | 0.4519 | 2.03 | 0.6831 | 0.798 | 3.80 | 1.87 | -284.47 | -- | 25.91 | -- |
| CeriBell Inc | -100.00bn | -100.00bn | 1.03bn | -- | -- | -- | -- | -- | -- | -- | -- | 0.5919 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.53 | -- | 0.4912 | -- | 74.47 | -- | 20.72 | -- | -- | -- |
| Pulse Biosciences Inc | 0.00 | -46.13m | 1.09bn | 56.00 | -- | 13.79 | -- | -- | -0.8069 | -0.8069 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -58.03 | -93.21 | -62.84 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
| Artivion Inc | 376.97m | -8.32m | 1.16bn | 1.50k | -- | 3.93 | 77.39 | 3.08 | -0.2076 | -0.2076 | 9.11 | 7.06 | 0.481 | 1.67 | 5.44 | 251,316.00 | -1.07 | -2.20 | -1.15 | -2.36 | 64.63 | 65.51 | -2.22 | -5.34 | 4.04 | 1.07 | 0.5177 | -- | 12.82 | 6.14 | -60.09 | -- | 5.13 | -- |
| Establishment Labs Holdings Inc | 151.35m | -83.20m | 1.18bn | 857.00 | -- | 26.30 | -- | 7.82 | -3.11 | -3.11 | 5.62 | 1.61 | 0.5307 | 0.8525 | 2.72 | 166,685.00 | -29.17 | -33.22 | -34.29 | -41.12 | 66.04 | 64.73 | -54.97 | -43.19 | 2.91 | -20.68 | 0.8114 | -- | 2.13 | 21.96 | -4.38 | -- | 69.16 | -- |
| BioLife Solutions Inc | 121.17m | -53.87m | 1.22bn | 409.00 | -- | 3.80 | -- | 10.09 | -1.21 | -1.64 | 2.69 | 6.97 | 0.2999 | 1.99 | 5.39 | 296,254.30 | -13.33 | -13.76 | -14.60 | -15.04 | 41.27 | 36.76 | -44.46 | -42.99 | 1.81 | -5.98 | 0.0651 | -- | -11.43 | 48.65 | 52.49 | -- | 86.35 | -- |
| Alphatec Holdings Inc | 572.74m | -177.87m | 1.32bn | 839.00 | -- | -- | -- | 2.30 | -1.27 | -1.27 | 4.08 | 0.1546 | 0.8089 | 1.11 | 7.73 | 682,644.80 | -25.12 | -30.97 | -32.00 | -39.47 | 69.47 | 66.02 | -31.06 | -46.22 | 1.15 | -3.66 | 0.9596 | -- | 37.45 | 39.38 | -23.36 | -- | 67.92 | -- |
| STAAR Surgical Co | 341.22m | 21.78m | 1.43bn | 1.06k | 66.24 | 3.34 | 51.70 | 4.19 | 0.4381 | 0.4381 | 6.90 | 8.69 | 0.6763 | 2.03 | 3.15 | 323,128.80 | 4.32 | 6.77 | 4.92 | 7.90 | 78.73 | 76.89 | 6.38 | 9.16 | 5.38 | -- | 0.0002 | 0.00 | 13.37 | 21.07 | -46.18 | 33.85 | 51.95 | -- |
Data as of Nov 12 2024. Currency figures normalised to Pulse Biosciences Inc's reporting currency: US Dollar USD
6.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.05m | 1.71% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 868.92k | 1.42% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 780.53k | 1.27% |
| Geode Capital Management LLCas of 30 Jun 2024 | 423.97k | 0.69% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 391.64k | 0.64% |
| Griffin Asset Management, Inc.as of 30 Sep 2024 | 257.45k | 0.42% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 181.17k | 0.30% |
| Westside Investment Management LLCas of 30 Jun 2024 | 63.60k | 0.10% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 50.55k | 0.08% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 45.40k | 0.07% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
